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Management options are antithyroid drugs, radioiodine ablation (RIA) and surgery. Antithyroid drugs are usually first-line treatment but up to 60% relapse. 2 3 In patients who relapse, options include a further course of antithyroid drugs, RIA or surgery. Both radioiodine and surgery have advantages and limitations for the patients to consider. Contraindications for surgery include pregnancy, recent neck surgery and severe, uncontrolled hyperthyroidism. RIA is contraindicated in pregnant or lactating women and in patients with severe eye disease. The choice of definitive treatment for Graves' disease in the absence of specific contraindications to surgery or radioiodine seems to be influenced by patients' and clinicians' preferences. [4] [5] [6] It is important to understand the reasons underlying patients' preferences as well as their values, concerns and experiences with treatments received.
This will enable clinicians to identify areas for improvement and help to inform future patients to facilitate decision making. Data on patients' views, concerns and satisfaction with radioiodine and surgical treatment of Graves' disease are sparse. Patient satisfaction studies of radioiodine in the UK demonstrated that 65%-87% of patients were satisfied with treatment and that just over half would recommend it to someone else. 7 8 Patient-reported complications included hoarseness of voice, vibrating sensation of the eyes, insomnia, forgetfulness, weight gain and depression. 9 Other studies have demonstrated high satisfaction rates following surgical treatment. 10 11 The aim of this study was to evaluate patients' concerns, experiences and satisfaction with regard to both RIA and thyroidectomy in the definitive management of Graves' disease in a single centre.
STUDY DESIGN
A cross-sectional patient survey was conducted. All adult patients who had treatment with surgery or radioactive iodine for the management of Graves' disease between January 2011 and June 2013 at Sheffield Teaching Hospitals NHS Foundation Trust were included. Participants were sent a postal questionnaire designed for this study. Questions regarding patients' concerns and reasons for choosing a particular treatment had predefined options as well as a free text section. Awareness of alternative treatments, involvement in the decision-making process, usefulness of aids to decision making and satisfaction with treatment were explored using 5-point Likert scale. The use of radioiodine or surgery was at the discretion of the treating endocrinologists and surgeons. Decisions were made in conjunction with patients following discussion of risks and benefits of both options.
Radioiodine ablation
In uncomplicated Graves' disease, 400-600 MBq radioiodine is given depending on the size of the thyroid gland. In patients with eye disease, prednisolone is given to prevent exacerbation 2-3 days before radioiodine treatment and continued for 3 weeks (30 mg/day for 1 week, 20 mg/day for 1 week and 10 mg/day for 1 week). Advice on safety precautions regarding avoidance of contact with pregnant women and young children, in addition to return to work information is provided to all patients. The treatment is provided as an outpatient and response monitored in future visits.
Surgery
Total thyroidectomy is the intended procedure in all these patients. Preoperative work-up includes an anaesthetic assessment, laryngoscopy and biochemical tests to ensure a euthyroid state and a normal calcium profile. Lugol's iodine (at a dose of 0.3 mL three times a day for 10 days before surgery) is routinely used to help reduce gland vascularity. In patients who have poor control of hyperthyroidism, monitored in-patient treatment with a combination of antithyroid drugs is carried out for 10 days before surgery. Patients are typically discharged the next day following a postoperative laryngoscopy, check of calcium levels and initiation of thyroxine. Further follow-up of thyroid biochemistry and any surgical complications is done in the surgical outpatient clinics.
Data analysis and statistics
Descriptive data were reported as frequencies or percentages. Categorical variables were compared using the Fisher's exact test. The levels of satisfaction, as assessed by Likert scale, were compared against 'recommendation of treatment' and 'patient involvement in decision making' using the Jonckheere-Terpstra test. The level of significance was set at p=0.05.
This survey was conducted as part of a service evaluation in relation to definitive treatment (surgery and radioiodine) provided in Sheffield Teaching Hospitals NHS Foundation Trust and was approved by the trust's clinical effectiveness unit. As patients were approached by post several months after definitive treatment and those willing to take part in the survey did so on a voluntary basis, no additional consent process or application to ethics committee was involved. As this was a service evaluation, additional data on demographic features such as age, gender or ethnicity were not formally recorded.
RESULTS
A total of 214 patients met the inclusion criteria. Responses were received from 136 patients (64%); 79 of 111 patients (71%) who had radioiodine and 57 of 103 patients (55%) who had surgery responded to the questionnaire. Table 1 shows the responses to questions relating to awareness of alternative treatment options, role in decision making and satisfaction with treatment.
Decision making
Of the 135 responders, 108 (80%) felt that they had some or detailed understanding of the alternative definitive treatment option and this was significantly more often reported in surgical patients ( p=0.007; Fisher's exact test). Of the 136 patients (84%), 114 agreed or strongly agreed that they were actively involved in the decision-making process. There was no significant difference between radioiodine and surgery groups (83% vs 86%, Fishers' exact test; p=0.443). There was a moderate positive correlation (Spearman's r=0.552; p<0.001) between responses to questions about 'awareness of alternative option' and 'involvement in decision making'.
Discussion with the doctor was considered to be the most useful decision-making tool for both radioiodine and surgical patients. Ninety-two per cent of patients who responded agreed that it aided their decision making. Information leaflets (55%) and discussion with friends and/or family (53%) were important to over half the patients. Over a third of patients (28/136; 37%) found the internet aided their decision making. Patients who underwent surgery were significantly more likely to report that their decision making was aided by 'friends/family' (p=0.03; Fisher's exact test).
Satisfaction
Of the 136 patients, 61 of 57 (80%) in the radioiodine group and 52 of 57 (91%) in the surgical group were satisfied or very satisfied with their treatment (table 1) . Overall, patients who underwent surgery were significantly more satisfied with treatment compared with those who underwent radioiodine therapy ( p=0.008; Fisher's exact test). When patients were asked "Would you recommend your definitive treatment to others?", there were no statistically significant differences between the groups (72% and 77% for radioiodine and surgery, respectively). Unsurprisingly, satisfied patients were more likely to recommend their treatment to others than unsatisfied patients ( Jonckheere-Terpstra test; p<0.001). When patients agreed to feeling involved in decision making with regard to treatment, they were more likely to be satisfied with treatment ( Jonckheere-Terpstra test; p<0.001).
Reported reasons for choice of treatment Table 2 lists the common reasons reported by patients for not choosing radioiodine or surgical treatment. There were 18 different reasons given by patients who had radioiodine for not choosing to have surgery. The 'idea of general anaesthetic and surgery' was the most common (n=29) followed by scarring and voice change. Uncommon reasons mentioned by just one patient and not listed in table 2 included having chronic obstructive pulmonary disease, not preferring inpatient stay, effectiveness of treatment, 'age', recent neck surgery, stigma of surgery (not wanting to worry friends and family) and wanting to get back to work as soon as possible. For those patients who had surgery, 15 different reasons were given for not choosing radioiodine. Avoiding close contact with children and/or pregnant women (n=26), the risk of remaining overactive and worsening eye disease were the most common reasons. Uncommon reasons mentioned by just one patient and not listed in table 2 included the desire to prevent recurrent eye disease, increased uncertainty regarding hormone levels, 'anxiety due to exposure', being 'still overactive' despite two attempts with antithyroid medications.
Prior and ongoing concerns with treatment received Table 3 lists concerns expressed by patients relating to treatments they had actually received. Seventy-six of 79 patients who underwent radioiodine therapy responded to at least one of the options relating to concerns before treatment. Common concerns expressed before RIA treatment included 'avoiding close contact in general' (83%), 'radioactive nature' of the treatment (77%) and risk of 'remaining hyperthyroid' (59%). Seventy-five of 79 patients responded to the question on ongoing concerns following RIA treatment. Common ongoing concerns included hypothyroidism (60%) and symptoms relating to the eyes (32%) and the skin (23%). Fifty-five of 57 surgical patients responded to at least one of the issues raised in the question regarding concerns before treatment. The 'idea of general anaesthetic and surgery' (63%), voice change (62%), swallowing problems (62%), scarring (58%) and bleeding/infection (50%) were concerns for at least half of the responders. The 55 patients who responded to the question relating to concerns after surgery raised issues including 'hypothyroidism' (43%), scarring (32%) and problems with eyes (27%), swallowing (25%) and voice (23%).
DISCUSSION
This study has shown that the majority of patients who underwent definitive treatment for Graves' disease had at least some understanding of the alternative treatment option available to them (80%), felt involved the decision-making process (84%) and were satisfied with their treatment (85%). Other studies in Graves' disease have shown similar levels of satisfaction with radioiodine and surgery. 4 10 A randomised controlled trial from Sweden comparing medical treatment, radioiodine and surgery in Graves' disease showed that 90% of patients from each of the three treatment groups were satisfied with treatment. 9 A key finding in this study was that involvement in decision making was found to be positively associated with satisfaction with treatment. This has been demonstrated in other situations and should provide further encouragement to clinicians to ensure patient involvement in making treatment decisions.
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The discussion with the doctor was considered to be the most important aid in decision making. Information leaflets were found to be useful in the decision-making process in 55% and the internet in 37% of patients. Given the use of internet by a significant proportion of patients, doctors may consider recommending reliable sources of web-based information. Discussion with friends and family was helpful in 53%; this was more marked in those undergoing surgery. The reasons for this are unclear.
Before radioiodine treatment, the concerns related to avoiding contacts with others, remaining hyperthyroid and the radioactive nature of the treatment. Remaining hyperthyroid after RIA was cited as a concern by 25% of patients undergoing surgery and 59% of patients undergoing RIA. However, the chance of remaining hyperthyroid is reported to be <20%. 14 15 Although, patients should be informed of this risk routinely, it should be reiterated that persistent hyperthyroidism is uncommon and that a further dose can effectively address the problem.
The idea of having surgery under general anaesthesia was the common reason for not undergoing surgery. This was also a concern for 63% of patients before surgery. In patients undergoing surgery, the main concerns were physical complications of scarring, swallowing problems, voice change and neck pain (table 3) . Twenty-three per cent of our patients felt that voice change was a concern after surgery. This is similar to those in another study, where 29% patients believed that they had experienced voice change. 10 Despite this, a greater number of patients were satisfied or very satisfied with surgery (91%) than radioiodine (80%). The higher satisfaction rates in the surgical group could be attributed to several reasons. Patients with more severe disease (with associated large goitre or thyroid eye disease) tend to be referred more often to surgery. 16 A greater relative improvement in well-being following treatment may therefore have contributed to higher scores. Patients in the surgical group are also more likely to have further consultations (with the surgical and anaesthetic teams in addition to endocrinologists) before treatment, arguably resulting in a greater opportunity to be involved in decision making and treatment planning. It is also likely that the surgery and radioiodine cohorts are likely to differ in demographic features as radioiodine is more likely to be used in elderly patients with comorbidity, while surgery in the young patients with children. This has not been explored as the relevant data on demographics were not collected, given the nature of the study (service evaluation).
The perception of being hypothyroid was the most common ongoing concern raised in both groups. This was greater in the radioiodine group (60%) compared with the surgery group (43%). This may be reflected in the difference between the predictability in developing hypothyroidism. Following surgery, the development of hypothyroidism is immediate and patients are started on thyroxine the next day. In contrast, after radioiodine the development of hypothyroidism may take months and is not easily predicted. Patients may be concerned about when they will develop hypothyroidism and how it will affect them.
This study has identified the common concerns in patients undergoing definitive treatment for Graves' disease. Clinicians should aim to provide detailed information and offer to discuss these issues when considering treatment options with patients. Addressing concerns in a shared decision-making process and empowering patients will improve patient satisfaction with whichever treatment they undergo. Our results also highlight that there are a wide range of reasons for choosing RIA or surgery. Some are concerns specific to only a few patients; but in these patients, they may be major factors in the decisionmaking process. In addition to common concerns, clinicians treating Graves' disease should also develop strategies for exploring the less common concerns.
The study has several limitations. The surgery group included patients from nearby hospitals who were referred by local endocrinologists at these hospitals specifically for thyroid surgery to be done by the endocrine surgeons in this centre. This may explain the relatively large number of patients undergoing surgery for Graves' disease at this centre. As the survey was conducted around 9-39 months after definitive treatment, the responses are subject to recall bias. This would be particularly relevant to some questions such as information on the provision of information and concerns before treatment. In a study of patients undergoing thyroid surgery, 69% of patients remembered only one or two of the possible complications mentioned prior to surgery and 12% could not remember any at hospital discharge. 17 The study did not use any validated questionnaires or scores to assess concerns related to voice, hypothyroidism or scar, as the main objective of the study was to assess overall satisfaction following definitive treatment and to gain an understanding into prior and ongoing concerns from a patient's perspective. Another limitation of the study is that an objective assessment of reported concerns was not done as it was outside the scope of the project.
CONCLUSION
The majority of patients are satisfied with their definitive treatment of Graves' disease, but those who underwent surgery are more satisfied than those who had RIA. Reasons for this may be multifactorial. The reasons underlying the choice of definitive treatment and concerns regarding treatment are several and vary
Main messages
▸ Most patients undergoing surgery or radioiodine ablation for Graves' disease were involved with decision making and were satisfied with their treatment. ▸ Patient involvement in the choice of definitive treatment is associated with increased satisfaction with treatment. ▸ Surgery is associated with higher levels of satisfaction compared with radioiodine.
from one patient to another. Understanding this will improve the provision of appropriate information for patients and will help them in the decision-making process. Patient involvement in the decision making is important and this involvement will increase their satisfaction with treatments received.
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